Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythemia Vera: A Multicenter Chart Review Study

Objective: This study aimed to evaluate real-life data on patterns of hydroxyurea prescription/use in polycythemia vera (PV). Materials and Methods: This retrospective chart review study included PV patients who had received hydroxyurea therapy for at least 2 months after PV diagnosis. Data were col...

Full description

Bibliographic Details
Published in:	Turkish Journal of Hematology
Main Authors:	Yahya Büyükaşık, Rıdvan Ali, Mehmet Turgut, Güray Saydam, Akif Selim Yavuz, Ali Ünal, Muhlis Cem Ar, Orhan Ayyıldız, Fevzi Altuntaş, Müfide Okay, Rafiye Çiftçiler, Özgür Meletli, Nur Soyer, Metban Mastanzade, Zeynep Güven, Teoman Soysal, Abdullah Karakuş, Tuğçe Nur Yiğenoğlu, Barış Uçar, Ece Gökçen, Tülin Tuğlular
Format:	Article
Language:	English
Published:	Turkish Society of Hematology 2020-08-01
Subjects:	polycythemia vera hydroxyurea treatment outcome
Online Access:	https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-40336

Similar Items

Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance
by: Kittitat Chiaranairungrot, et al.
Published: (2022-12-01)

Hydroxyurea-induced melanonychia
by: Michael G. Buontempo, BS, et al.
Published: (2023-12-01)

Hydroxyurea-induced Tooth Discoloration
by: Muhammed Okuyucu, et al.
Published: (2020-02-01)

Acute myocardial infarction and polycythemia rubra vera: The double effect of treatment with hydroxyurea
by: Xhevdet Tahiraj, MD, et al.
Published: (2024-08-01)

In Vitro Hb Production in Β-thalassemia Patients Is Not a Predictor of Clinical Responsiveness to Hydroxyurea
by: Mohammad Reza MAHDAVI, et al.
Published: (2017-06-01)

Hydroxyurea treatment inhibits proliferation of Cryptococcus neoformans in mice
by: Kaushlendra eTripathi, et al.
Published: (2012-05-01)

Side Effects of Hydroxyurea in Patients with Major and Intermediat B-Thalassemia
by: Ali Ghasemi, et al.
Published: (2015-10-01)

Side Effects of Hydroxyurea in Patients with Major and Intermediat B-Thalassemia
by: Ali Ghasemi, et al.
Published: (2012-10-01)

Dermatomyositis-Like Eruption Associated with Hydroxyurea Therapy
by: Katarzyna Winkel, et al.
Published: (2025-06-01)

Barriers and Facilitators of Use of Hydroxyurea among Children with Sickle Cell Disease: Experiences of Stakeholders in Tanzania
by: Manase Kilonzi, et al.
Published: (2021-11-01)

Hydroxyurea ulcers of unusual location: a case report and review of literature
by: Miguel Mansilla-Polo, et al.
Published: (2023-11-01)

Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea
by: I A Lagunju, et al.
Published: (2013-01-01)

Dermatomyositis-like Eruptions, Hydroxyurea-Associated Squamous Dysplasia, and Nonmelanoma Skin Cancer: A Case Report and Systematic Review
by: Giorgia Di Marco, et al.
Published: (2025-03-01)

Hydroxyurea ameliorates mouse hypoxia through inducing embryonic hemoglobin
by: ZHOU Xiaoying, et al.
Published: (2023-01-01)

Hydroxyurea granules for the management of sickle cell disease in children
by: Grace Lovia Allotey-Babington, et al.
Published: (2022-07-01)

Adherence to Hydroxyurea and Patients’ Perceptions of Sickle Cell Disease and Hydroxyurea: A Cross-Sectional Study
by: Mohammed Ali Madkhali, et al.
Published: (2024-01-01)

Prognostic value of modified criteria for hydroxyurea resistance or intolerance in patients with high‐risk essential thrombocythemia
by: Young Hoon Park, et al.
Published: (2023-04-01)

Impact of hydroxyurea on clinical and biological parameters of sickle cell anemia in children in Abidjan
by: MIREILLE YAYO- AYE, et al.
Published: (2024-02-01)

Successful Management of Hydroxyurea-induced Leg Ulcers in Essential Thrombocythemia: Report of 3 Cases
by: Jihane Abou Rahal, et al.
Published: (2013-06-01)

Hydroxyurea and nonmelanoma skin cancers: Report of three cases and review of the literature
by: Roš Tatjana, et al.
Published: (2017-01-01)

Optimization of hydroxyurea in sickle cell disease in Brazil
by: Clarisse Lobo, et al.
Published: (2025-04-01)

Influence of hydroxyurea on tubular phosphate handling in sickle cell nephropathy
by: Gabriela Araujo de Abreu, et al.
Published: (2024-11-01)

Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched‐cohort analysis
by: Michael R. Grunwald, et al.
Published: (2024-08-01)

Study on hydroxyurea response in hemoglobinopathies patients using genetic markers and liquid erythroid cultures
by: Serena Sclafani, et al.
Published: (2016-12-01)

Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia
by: Gohal GA, et al.
Published: (2022-11-01)

Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment
by: Fabia Neves, et al.
Published: (2012-01-01)

Heterofullerene MC<sub>59</sub> (M = B, Si, Al) as Potential Carriers for Hydroxyurea Drug Delivery
by: Peng Wang, et al.
Published: (2021-01-01)

Study of seminal fluid parameters and fertility of male sickle-cell disease patients and potential impact of hydroxyurea treatment
by: Lulup K Sahoo, et al.
Published: (2016-01-01)

Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project
by: Srdan Verstovsek, et al.
Published: (2023-07-01)

Multiple Skin Cancers Associated With Hydroxyurea: Case Report and Review of Literature
by: Safoura Shakoei, et al.
Published: (2025-08-01)

Efficacy and safety of hydroxyurea therapy on patients with β-thalassemia: a systematic review and meta-analysis
by: Tianmin Huang, et al.
Published: (2025-01-01)

Evaluation of pediatric hydroxyurea prescriptions for patients with sickle cell disease
by: Fernanda Alice Tanimoto Duque, et al.
Published: (2022-11-01)

Quercetin reduces hydroxyurea induced cytotoxicity in immortalized mouse aortic endothelial cells
by: Zachary M. Kiser, et al.
Published: (2017-05-01)

Relationship between Use of Hydroxyurea and Cholelithiasis in Patients with Major and Intermediate β-thalassemia
by: H. Karami, M.D., et al.
Published: (2007-01-01)

Leukoreduction and hydroxyurea in malignant pertussis: A case series
by: Nedaa Aldairi, et al.
Published: (2020-12-01)

Antiradical, Chelating and Antioxidant Activities of Hydroxamic Acids and Hydroxyureas
by: Branka Zorc, et al.
Published: (2011-07-01)

Apparent Stability Constant of Zr(Ⅳ)-Hydroxyurea Complex With pH Potentiometric Titration
by: YANG Ya-ya, et al.
Published: (2022-04-01)

Functionalized boron doped graphene (BGP) as smart nanocarrier for delivery of hydroxyurea (HU) drug
by: Terkumbur E. Gber, et al.
Published: (2023-12-01)

Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents
by: Paavani S. Reddy, et al.
Published: (2022-12-01)

Morbidity pattern and impact of hydroxyurea therapy among sickle cell patients in Raipur district of Chhattisgarh
by: Divyansh Vaibhav, et al.
Published: (2024-05-01)